<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05099211</url>
  </required_header>
  <id_info>
    <org_study_id>COTTET CHU Dijon 2018</org_study_id>
    <nct_id>NCT05099211</nct_id>
  </id_info>
  <brief_title>Neuromuscular Deconditioning and Reconditioning in Colon Cancer Patients: an APA Muscle Rendorcement Program</brief_title>
  <acronym>REMUSCLON</acronym>
  <official_title>Neuromuscular Deconditioning and Reconditioning in Colon Cancer Patients: A Pilot Study of an APA Muscle Rendorcement Program</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire Dijon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire Dijon</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Colon cancer is a real public health problem with more than 46,000 new cases diagnosed per&#xD;
      year in France and about 650 cases in Burgundy. Muscle deconditioning (MD), which is&#xD;
      characterized by a loss of muscle mass and function, is a frequent consequence in cancer&#xD;
      patients and conditions the prognosis. Therefore, it is essential to understand its complex&#xD;
      etiology in oncology in order to address the real need for therapeutic countermeasures in&#xD;
      clinical practice. DM is a multifactorial process that is exacerbated by therapies. It&#xD;
      induces neurogenic and muscular alterations that can profoundly affect patients' quality of&#xD;
      life.&#xD;
&#xD;
      Currently, analyses of this phenomenon in oncology have been limited essentially to a global&#xD;
      evaluation of physical performance, neglecting the muscular and nervous nature of the&#xD;
      adaptations responsible for it.&#xD;
&#xD;
      Most studies analyzing the therapeutic effects of physical activity (PA) have shown numerous&#xD;
      physiological and psychological benefits of aerobic exercise. However, this form of PA is&#xD;
      still not very effective in preserving muscle mass.&#xD;
&#xD;
      Only muscle strengthening can have an anabolic effect by accelerating the rate of protein&#xD;
      synthesis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">May 2024</completion_date>
  <primary_completion_date type="Anticipated">May 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Acceptability of the program in terms of the number of sessions attended</measure>
    <time_frame>Up to Week 30 (evaluation 4) for patients</time_frame>
    <description>Tolerance in terms of level of effort and pain will be tested at each session and will condition the continuation or not of the sessions and therefore acceptability</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Acceptability of the program in terms of the number of sessions attended</measure>
    <time_frame>Up to Week 1 (evaluation 1) for healthy patients</time_frame>
    <description>Tolerance in terms of level of effort and pain will be tested at each session and will condition the continuation or not of the sessions and therefore acceptability</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Colon Cancer</condition>
  <condition>Muscle Strengthening</condition>
  <arm_group>
    <arm_group_label>Patients muscle strengthening</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Aerobic Training Patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy patients</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Muscle biopsies</intervention_name>
    <description>Optional&#xD;
In pre-training:&#xD;
Biopsy performed during the digestive surgery procedure&#xD;
Final evaluation (minimum 1 day and maximum 7 days after the last training session): biopsy performed in the digestive surgery department.</description>
    <arm_group_label>Aerobic Training Patients</arm_group_label>
    <arm_group_label>Patients muscle strengthening</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Muscle Strengthening</intervention_name>
    <description>3 sessions per week for 18 weeks. Duration: 1 hour Training on different strength training machines for the main muscle groups of the lower and upper limbs. The training load will be gradually increased over the sessions.</description>
    <arm_group_label>Patients muscle strengthening</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Blood and urine samples</intervention_name>
    <description>fasting blood sample taken at assessments 1, 2, 3 and 4 for patients and assessment 1 for controls</description>
    <arm_group_label>Aerobic Training Patients</arm_group_label>
    <arm_group_label>Healthy patients</arm_group_label>
    <arm_group_label>Patients muscle strengthening</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Aerobic Training</intervention_name>
    <description>3 sessions per week for 18 weeks. Duration: 1 hour Training on a &quot;classic&quot; pedal bicycle (called an ergocycle). The intensity and duration of the training will be gradually increased over the sessions and according to the patient's abilities.</description>
    <arm_group_label>Aerobic Training Patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Evaluation 1 pre-surgery</intervention_name>
    <description>Carried out at least 15 days before surgery&#xD;
st visit:&#xD;
Neuromuscular tests&#xD;
Nutritional assessment&#xD;
Body composition&#xD;
nd visit:&#xD;
VO2max&#xD;
Functional tests Home: Psychometric tests of quality of life + IPAQ Test</description>
    <arm_group_label>Aerobic Training Patients</arm_group_label>
    <arm_group_label>Healthy patients</arm_group_label>
    <arm_group_label>Patients muscle strengthening</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Evaluation 2 post-surgery</intervention_name>
    <description>st visit:&#xD;
neuromuscular tests&#xD;
Nutritional assessment&#xD;
nd visit:&#xD;
Body composition&#xD;
Functional tests&#xD;
Familiarization with training equipment Home: Psychometric tests of quality of life</description>
    <arm_group_label>Aerobic Training Patients</arm_group_label>
    <arm_group_label>Patients muscle strengthening</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Intermediate Evaluation 3</intervention_name>
    <description>performed 9 weeks after the beginning of training Identical tests to evaluation 1</description>
    <arm_group_label>Aerobic Training Patients</arm_group_label>
    <arm_group_label>Patients muscle strengthening</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Final post-training evaluation 4</intervention_name>
    <description>Tests identical to evaluation 1</description>
    <arm_group_label>Aerobic Training Patients</arm_group_label>
    <arm_group_label>Patients muscle strengthening</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient Inclusion Criteria :&#xD;
&#xD;
          -  Adult patients who are ≤ 80 years old&#xD;
&#xD;
          -  with a first diagnosis of colon cancer, regardless of TNM stage&#xD;
&#xD;
          -  to undergo a scheduled excision surgery&#xD;
&#xD;
          -  and post-operative chemotherapy treatment&#xD;
&#xD;
          -  with WHO stage = 0 at visits V1 and V2&#xD;
&#xD;
          -  having given their written consent&#xD;
&#xD;
          -  living close to the participating center (&lt;30 km)&#xD;
&#xD;
          -  ability to understand instructions&#xD;
&#xD;
          -  with the consent of the surgeon and oncologist to the practice of physical activity&#xD;
&#xD;
          -  having no medical contraindication to the physical activity program, in particular&#xD;
             ostomy&#xD;
&#xD;
        Criteria for inclusion of healthy subjects :&#xD;
&#xD;
          -  Adult who is ≤ 80 years old&#xD;
&#xD;
          -  matched by gender, age and BMI to a patient&#xD;
&#xD;
          -  with WHO stage = 0 at visits V1 and V2&#xD;
&#xD;
          -  no medical contraindications to the program&#xD;
&#xD;
          -  having given written consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Criteria for exclusion of patients and healthy subjects :&#xD;
&#xD;
          -  Protected Adult&#xD;
&#xD;
          -  Person not affiliated to national health insurance&#xD;
&#xD;
          -  Pregnant or breastfeeding woman&#xD;
&#xD;
          -  hypersensitivity to lidocaine&#xD;
&#xD;
          -  uncontrolled hypertension&#xD;
&#xD;
          -  Suffers from unstable diabetes of any type&#xD;
&#xD;
          -  Suffers from heart disease. Pre-surgical VO2 test will confirm authorization.&#xD;
&#xD;
          -  With a BMI &gt; 30&#xD;
&#xD;
          -  Affected by any condition likely to complicate the performance of physical activity&#xD;
             (neurological, psychiatric, neuromuscular disorders, severe osteoporosis)&#xD;
&#xD;
          -  Person who has been regularly physically active in the last 2 months (strength and/or&#xD;
             aerobic training) ≥ 150 min/week&#xD;
&#xD;
        Patient-specific exclusion criteria&#xD;
&#xD;
          -  Patient with rectal cancer or other evolving cancer&#xD;
&#xD;
          -  Presence of an ostomy (complicates the practice of physical activity)&#xD;
&#xD;
        Exclusion criteria specific to healthy subjects&#xD;
&#xD;
        - Subject has had cancer in the last 5 years&#xD;
&#xD;
        Criteria for exclusion of patients and healthy subjects for biopsy:&#xD;
&#xD;
          -  Person with keloidosis&#xD;
&#xD;
          -  Person with bleeding disorders, and/or on anticoagulant and antiaggregant medication&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Anaïs GOUTERON</last_name>
    <phone>03 80 29 38 15</phone>
    <email>anais.gouteron@chu-dijon.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chu Dijon Bourgogne</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Anaïs GOUTERON</last_name>
      <phone>03 80 29 38 15</phone>
      <email>anais.gouteron@chu-dijon.fr</email>
    </contact>
    <contact_backup>
      <last_name>Vanessa COTTET</last_name>
      <phone>03 80 39 34 87</phone>
      <email>vanessa.cottet@u-bourgogne.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 12, 2021</study_first_submitted>
  <study_first_submitted_qc>October 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 29, 2021</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colonic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

